Alopecia Areata Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Therapies, Epidemiology, Revenue, Statistics, Medication, and Companies by DelveInsight
Alopecia Areata companies are Arcutis Biotherapeutics, Bioniz Therapeutics, Reistone Biopharma Company, Pfizer, Suzhou Zelgen Biopharmaceuticals, Eli Lilly, Incyte Corporation, Aclaris Therapeutics, Legacy Healthcare, Concert Pharmaceuticals, LEO Pharma, Bristol-Myers Squibb, and others.
(Albany, USA) DelveInsight's " Alopecia Areata Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Alopecia Areata, historical and forecasted epidemiology as well as the Alopecia Areata market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The market report on Alopecia Areata presents up-to-date information on treatment approaches, emerging medications, the market share of different therapies, and the current as well as projected Alopecia Areata market size from 2020 to 2034, across seven major markets. The report includes details on the prevailing treatment practices and guidelines for Alopecia Areata, along with an analysis of market drivers, barriers, and unmet medical needs. This comprehensive assessment aims to identify the most promising opportunities and evaluate the overall potential of the Alopecia Areata market.
Some facts of the Alopecia Areata Market Report are:
According to DelveInsight, Alopecia Areata Market is expected to grow at a CAGR of ~27% by 2034.
According to DelveInsight's patient-based forecasting model, the total market size of Alopecia Areata in the 7MM was around USD 180 million in 2023.
Leading Alopecia Areata companies working in the market are Arcutis Biotherapeutics, Bioniz Therapeutics, Reistone Biopharma Company, Pfizer, Suzhou Zelgen Biopharmaceuticals, Eli Lilly, Incyte Corporation, Aclaris Therapeutics, Legacy Healthcare, Concert Pharmaceuticals, LEO Pharma, Bristol-Myers Squibb, And Many Others
Key Alopecia Areata Therapies expected to launch in the market are Abatacept, Tralokinumab, Secukinumab, BNZ 1, Ritlecitinib, Ifidancitinib, Coacillium topical, Delgocitinib, Etrasimod, Brepocitinib, ATI 1777, Baricitinib, and several others.
The increasing R&D investments for strong Alopecia Areata pipeline candidates by prominent players such as Arcutis Biotherapeutics, Bioniz Therapeutics, Pfizer, Eli Lilly and Company, Reistone Biopharma Company, Concert Pharmaceuticals, and others will contribute positively to the Alopecia Areata treatment landscape in the forthcoming years.
Alopecia Areata Overview
Alopecia areata is an autoimmune disorder that results in sudden hair loss. It occurs when the immune system mistakenly targets hair follicles, causing them to shrink and enter a dormant phase. This leads to hair thinning or complete hair loss in round or oval patches on the scalp or other parts of the body.
The exact cause of alopecia areata is not fully understood, but it is believed to involve a combination of genetic and environmental factors. It can affect individuals of any age, gender, or ethnic background.
While alopecia areata is generally not a life-threatening condition, it can have a significant psychological and emotional impact on those affected. The unpredictable nature of hair loss and its potential for recurrence can cause distress and self-esteem issues.
There is currently no known cure for alopecia areata, but various treatment options aim to stimulate hair regrowth and manage the condition. These may include topical corticosteroids, topical immunotherapy, oral medications, and injectable medications. Hairpieces, wigs, or cosmetic camouflage techniques can also be utilized to cover areas of hair loss.
Learn more about Alopecia Areata treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Alopecia Areata Treatment Market
Alopecia Areata Market
The Alopecia Areata market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Alopecia Areata market trends by analyzing the impact of current Alopecia Areata therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.
This segment gives a thorough detail of the Alopecia Areata market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Alopecia Areata market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Alopecia Areata market in 7MM is expected to witness a major change in the study period 2020-2034.
Alopecia Areata Epidemiology
The Alopecia Areata epidemiology section provides insights into the historical and current Alopecia Areata patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Alopecia Areata market report also provides the diagnosed patient pool, trends, and assumptions.
Alopecia Areata Drugs Uptake
This section focuses on the uptake rate of the potential Alopecia Areata drugs recently launched in the Alopecia Areata market or expected to be launched in 2020-2034. The analysis covers the Alopecia Areata market uptake by drugs, patient uptake by therapies, and sales of each drug.
Alopecia Areata Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Alopecia Areata market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Alopecia Areata Pipeline Development Activities
The Alopecia Areata report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses key Alopecia Areata companies involved in developing targeted therapeutics.
Alopecia Areata Therapeutics Assessment
Major key companies are working proactively in the Alopecia Areata Therapeutics market to develop novel therapies which will drive the Alopecia Areata treatment markets in the upcoming years are Arcutis Biotherapeutics, Bioniz Therapeutics, Reistone Biopharma Company, Pfizer, Suzhou Zelgen Biopharmaceuticals, Eli Lilly, Incyte Corporation, Aclaris Therapeutics, Legacy Healthcare, Concert Pharmaceuticals, LEO Pharma, Bristol-Myers Squibb, And Many Others.
Scope of the Alopecia Areata Market Report:
Coverage: 7MM
Study Period: 2020-2034
Alopecia Areata Companies: Arcutis Biotherapeutics, Bioniz Therapeutics, Pfizer, Eli Lilly and Company, Reistone Biopharma Company, Concert Pharmaceuticals, Suzhou Zelgen Biopharmaceuticals, Legacy Healthcare, Arena Pharmaceuticals, LEO Pharma, Aclaris Therapeutics, Bristol-Myers Squibb, Novartis, and many others.
Alopecia Areata Drugs: Abatacept, Tralokinumab, Secukinumab, BNZ 1, Ritlecitinib, Ifidancitinib, Coacillium topical, Delgocitinib, Etrasimod, Brepocitinib, ATI 1777, Baricitinib, and several others.
Alopecia Areata Report Key Insights
1. Alopecia Areata Patient Population
2. Alopecia Areata Market Size and Trends
3. Key Cross Competition in the Alopecia Areata Market
4. Alopecia Areata Market Dynamics (Key Drivers and Barriers)
5. Alopecia Areata Market Opportunities
6. Alopecia Areata Therapeutic Approaches
7. Alopecia Areata Pipeline Analysis
8. Alopecia Areata Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Alopecia Areata Market
Table of Contents
1. Key Insights
2. Executive Summary
3. Alopecia Areata Competitive Intelligence Analysis
4. Alopecia Areata Market Overview at a Glance
5. Alopecia Areata Disease Background and Overview
6. Alopecia Areata Patient Journey
7. Alopecia Areata Epidemiology and Patient Population
8. Alopecia Areata Treatment Algorithm, Current Treatment, and Medical Practices
9. Alopecia Areata Unmet Needs
10. Key Endpoints of Alopecia Areata Treatment
11. Alopecia Areata Marketed Products
12. Alopecia Areata Emerging Therapies
13. Alopecia Areata Seven Major Market Analysis
14. Attribute Analysis
15. Alopecia Areata Market Outlook (7 major markets)
16. Alopecia Areata Access and Reimbursement Overview
17. KOL Views on the Alopecia Areata Market
18. Alopecia Areata Market Drivers
19. Alopecia Areata Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
20 minutes ago
- Globe and Mail
Abbott Taps Growing TMVR Market With Tendyne System
Abbott Laboratories ABT recently received Food and Drug Administration ('FDA') approval for its Tendyne transcatheter mitral valve replacement (TMVR) system. The Tendyne system replaces mitral valves that are not functioning properly due to severe mitral annular calcification (MAC). The Tendyne system expands the company's comprehensive Structural Heart portfolio. The rising prevalence of mitral valve diseases, growing preferences for minimally invasive procedures and expanding geriatric population has driven the adoption of TMVR system. Investors are eyeing this fast-growing market, which is projected to witness a compound annual growth rate of 20% from 2025 to 2030 (Per a Medi-Tech Insights report). MAC stiffens the structure of the mitral valve and can lead to mitral regurgitation or stenosis that disrupts the heart's ability to pump blood effectively. The complex nature of this mitral valve disease and patients' specific needs and health conditions can pose challenges for surgical correction. The Tendyne system offers an alternative, minimally invasive way to replace the valve of patients with severe MAC who are at high risk for open-heart surgery. The innovative and unique design of the Tendyne system and the valve's availability in multiple sizes allow it to adapt to a range of patient anatomies. The self-expanding valve is delivered through a small incision in the chest and then advanced into the heart to replace the mitral valve. The valve is fully repositionable and retrievable during implantation, allowing for the best possible outcome for people requiring a valve replacement. Offerings By ABT's Peers in the Structural Heart Field Edwards Lifesciences EW makes significant investments in the development of transcatheter heart valve repair and replacement technologies designed to treat mitral and tricuspid valve diseases. The company's PASCAL Precision system addresses the needs of patients with mitral or tricuspid regurgitation through leaflet approximation. The EVOQUE system is the world's first transcatheter tricuspid valve replacement therapy to receive regulatory approval. It addresses tricuspid valve regurgitation by replacing the native valve with a bioprosthetic valve. In addition, SAPIEN M3 transcatheter mitral valve replacement system is designed specifically for patients with symptomatic mitral regurgitation. Medtronic 's MDT Structural Heart & Aortic division offers therapies for heart valve disorders and aortic disease. Key products include the CoreValve family (Evolut PRO, PRO+, FX, FX+ TAVR systems), surgical valve replacement and repair solutions (tissue and mechanical), blood-handling systems, surgical ablation technologies, and positioning/stabilization tools. The company also provides endovascular stent grafts and accessories like the Endurant II Stent Graft System (abdominal aortic aneurysms), Valiant Captivia Thoracic Stent Graft System (thoracic repair) and Heli-FX EndoAnchor System. ABT Price Performance In the past year, Abbott shares have surged 19.2%, outperforming the industry's 6.2% growth. The S&P 500 composite grew 17.8% in the same period. Image Source: Zacks Investment Research Discounted Valuation ABT currently trades at a forward 12-month Price-to-Sales (P/S) of 4.87X compared with the industry average of 5.56X. Image Source: Zacks Investment Research ABT Stock Estimate Trend In the past 30 days, Tempus AI's EPS estimate has moved south 0.2% for 2025. Image Source: Zacks Investment Research ABT stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops." Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report This article originally published on Zacks Investment Research (
Globe and Mail
20 minutes ago
- Globe and Mail
NIH Contract Expands DLH's Position as a Digital Transformation and Cybersecurity Leader
ATLANTA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) ('DLH' or the 'Company'), a leading provider of digital transformation and cyber security, science research and development, and systems engineering and integration, today announced that it has been awarded a task order valued at up to $46.9 million to continue providing information technology services including enterprise IT systems management, cyber security, software development, cloud computing, and more to the National Institutes of Health's Office of Information Technology ('OIT'). OIT plays a central role in providing and supporting the information technology resources necessary to execute NIH's critical health missions. 'With our unique position at the intersection of scientific research and advanced technology, DLH remains a natural partner for innovation alongside the National Institutes of Health,' said Zach Parker, DLH President and CEO. 'DLH engineers, application developers, and IT will continue to bring their industry-leading information technology, systems integration, and customer support expertise to provide crucial support for this customer while also asked to conduct technology assessments and impact strategic modernization plans.' This $46.9 million task order includes a base period and multiple options aggregating to a three-year period of performance. Through this award, DLH will leverage a comprehensive suite of digital transformation and cyber security solutions to support approximately 7,000 end-customers. As part of this new effort, DLH will design and implement a cloud migration strategy built on partnerships with leading commercial CSP vendors including Azure, AWS, and Google. 'DLH will continue to test, validate, refine, and incubate bold new ideas and innovation on behalf of the vital work our customers carry out,' said Diane Yarnell, President, Health IT. 'Our experts deliver full project management life-cycle solutions to modernize IT, improve the customer experience and business processes, optimize systems, train personnel, and integrate emerging technologies such as artificial intelligence.' About DLH DLH (NASDAQ: DLHC) enhances technology, public health, and cyber security readiness missions through science, technology, cyber, and engineering solutions and services. Our experts solve some of the most complex and critical missions faced by customers today, leveraging digital transformation, artificial intelligence, advanced analytics, cloud-based applications, telehealth systems, and more. With over 2,400 employees dedicated to the idea that 'Your Mission is Our Passion,' DLH brings a unique combination of technology, innovation, and world-class expertise, to improve lives across the globe. For more information, visit Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or DLH`s future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that the Company or its management 'believes', 'expects', 'anticipates', 'plans', 'intends' and similar expressions) should be considered forward looking statements that involve risks and uncertainties which could cause actual events or DLH's actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements in this release include, among others, statements regarding estimates of future revenues, operating income, earnings and cash flow. These statements reflect our belief and assumptions as to future events that may not prove to be accurate. Our actual results may differ materially from such forward-looking statements made in this release due to a variety of factors, including: the risk that we will not realize the anticipated benefits of acquisitions (including anticipated future financial performance and results); the diversion of management's attention from normal daily operations of the business and the challenges of managing larger and more widespread operations; the inability to retain employees and customers; contract awards in connection with re-competes for present business and/or competition for new business; our ability to manage our debt obligations; compliance with bank financial and other covenants; changes in client budgetary priorities; government contract procurement (such as bid and award protests, small business set asides, loss of work due to organizational conflicts of interest, etc.) and termination risks; the impact of inflation and higher interest rates; and other risks described in our SEC filings. For a discussion of such risks and uncertainties which could cause actual results to differ from those contained in the forward-looking statements, see 'Risk Factors' in the Company's periodic reports filed with the SEC, including our Annual Report on Form 10-K for the fiscal year ended September 30, 2024 as well as subsequent reports filed thereafter. The forward-looking statements contained herein are not historical facts, but rather are based on current expectations, estimates, assumptions and projections about our industry and business. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company does not assume any responsibility for updating forward-looking statements, except as may be required by law.
CBC
21 minutes ago
- CBC
Rabbits with strange horn-like growths spotted in Colorado
Social Sharing A group of rabbits in Colorado with grotesque, horn-like growths may seem straight out of a low-budget horror film, but scientists say there's no reason to be spooked — the furry creatures merely have a relatively common virus. The cottontails recently spotted in Fort Collins are infected with the mostly harmless Shope papillomavirus, which causes wart-like growths that protrude from their faces like metastasizing horns. Viral photos have inspired a fluffle of unflattering nicknames, including "Frankenstein bunnies," "demon rabbits" and "zombie rabbits." But their affliction is nothing new, with the virus inspiring ancient folklore and fuelling scientific research nearly 100 years ago. The virus likely influenced the centuries-old jackalope myth in North America, which told of a rabbit with antlers or horns, among other animal variations. The disease in rabbits also contributed to scientists' knowledge about the connection between viruses and cancer, such as the human papillomavirus, which causes cervical cancer. The virus in rabbits was named after Dr. Richard E. Shope, a professor at the Rockefeller University who discovered the disease in cottontails in the 1930s. News about the rabbit sightings in Fort Collins, 105 kilometres (65 miles) north of Denver, got attention after residents started spotting them around town and posting pictures. Kara Van Hoose, a spokesperson for Colorado Parks and Wildlife, told The Associated Press on Wednesday that the agency has been getting calls about the rabbits seen in Fort Collins. She said it's not uncommon to see infected rabbits, especially in the summer, when the fleas and ticks that spread the virus are most active. The virus can spread from rabbit to rabbit but not to other species, including humans and pets, she said. The growths resemble warts but can look like horns if they grow longer, Van Hoose said. The growths don't harm rabbits unless they grow on their eyes or mouths and interfere with eating. Rabbits' immune systems are able to fight the virus and, once they do, the growths will disappear, she said.
